drugset
drugset / Trial / NCT06169891

A Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout

NCT06169891 ↗

Phase 3 Unknown 500 enrolled Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the efficacy and safety of recombinant anti-IL-1β humanized monoclonal antibody injection in Chinese participants with acute gout.

Timeline

Start
2023-12
Primary completion
2024-12
Completion
2025-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator BETAMETHASONE DIPROPIONATE Small molecule 1 ml Intramuscular
Subject SSGJ-613 Monoclonal antibody 200 mg Subcutaneous

Indications

gout